Showing results (481-490 of 831) with videos related to

Sort By:
Pageof 84
Blood|April 30, 2010
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemiaKumudha Balakrishnan, Dushyant Verma, Susan O'Brien, et al.
Blood|October 5, 2014
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Constantine S Tam, Susan O'Brien, William Plunkett, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2014
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosisElias Jabbour, Hady Ghanem, Xuelin Huang, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Haematologica|June 15, 2019
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single centerYucai Wang, Marcella A Tschautscher, Kari G Rabe, et al.
Cancer|July 5, 2012
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemiaTait D Shanafelt, Timothy G Call, Clive S Zent, et al.
Blood Advances|April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sitesAnthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
Blood|November 5, 2010
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemiaTait D Shanafelt, Matthew T Drake, Matthew J Maurer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 11, 2013
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemiaChris L Pashos, Christopher R Flowers, Neil E Kay, et al.
Oncotarget|January 17, 2019
Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapySutapa Sinha, Justin C Boysen, Kari G Chaffee, et al.
Pageof 84